Drug treatment for myotonia

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 6, 2006, Pages

  Trip, Jeroen ^a   Drost, Gea G ^b   van Engelen, Baziel GM ^b   Faber, C G ^c  

^a Neurologist   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Neuromuscular Center Nijmegen ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MYOTONIA; MYOTONIC DYSTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HUMANS; MYOTONIA; MYOTONIC DYSTROPHY; RANDOMIZED CONTROLLED TRIALS;

EID: 33645505922     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004762.pub2     Document Type: Review

References (110)

1. Antonini G, Vichi R, Leardi MG, Pennisi E, Monza GC, Millefiorini M. Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial. Neurology 1990;40(9):1473-4.
2. Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology 1983;33(5):599-603.
3. Finlay M. A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry 1982;45(5):461-3.
4. Gascon GG, Staton RD, Patterson BD, Konewko PJ, Wilson H, Carlson KM, et al. A pilot controlled study of the use of imipramine to reduce myotonia. American Journal of Physical Medicine & Rehabilitation 1989;68(5):215-20.
5. Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedipine in the treatment of myotonia in myotonic dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry 1987;50(2):199-206.
6. Kratz R, Hawley RJ, Jackson LK, Gheen I. Treatment of myotonia with mexiletine. Muscle & Nerve (Abstract) 1986;9(Suppl 5):199.
7. Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurologica Scandinavica 1992;86(4):371-5.
8. Lewis I. Trial of diazepam in myotonia - A controlled clinical trial. Neurology 1966;16(8):831-6.
9. Leyburn P, Walton JN. The treatment of myotonia: A controlled clinical trial. Brain 1960;82:81-9.
10. Munsat TL. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology 1967;17(4):359-67.
11. Alfonsi E, Merlo IM, Tonini M, Ravaglia S, Brugnoni R, Gozzini A, et al. Efficacy of propafenone in paramyotonia congenita. Neurology 2007;68(13):1080.
12. Backman E, Henriksson KG. Effect of sodium selenite and vitamin E treatment in myotonic dystrophy. Journal of Internal Medicine 1990;228(6):577-81.
13. Benstead TJ, Camfield PR, King DB. Treatment of paramyotonia congenita with acetazolamide. Canadian Journal of Neurological Sciences 1987;14(2):156-8.
14. Birnberger KL, Rudel R, Struppler A. Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin. Journal of Neurology 1975;210(2):99-110.
15. Brumback RA, Carlson KM. The depression of myotonic dystrophy: response to imipramine. Journal of Neurology, Neurosurgery, and Psychiatry 1983;46(6):587-8.
16. Cook JD, Henderson-Tilton AC. Beneficial response to a calcium channel antagonist in myotonic syndromes. Neurology 1984;34(Suppl 1):193-4.
17. Durelli L, Mutani R, Fassio F, Satta A, Bartoli E. Taurine and hyperexcitable human muscle: effects of taurine on potassium-induced hyperexcitability of dystrophic myotonic and normal muscles. Annals of Neurology 1982;11(3):258-65.
18. Garai O. The treatment of dystrophia myotonica with A.C.T.H. Journal of Neurology, Neurosurgery and Psychiatry 1954;17(1):83-6.
19. Geschwind N, Simpson JA. Procaine amide in the treatment of myotonia. Brain 1955;78(1):81-91.
20. Griggs RC, Moxley RT 3rd, Riggs JE, Engel WK. Effect of acetazolamide on myotonia. Transactions of the American Neurological Association 1977;102:133-5.
21. Griggs RC, Moxley RT 3rd, Riggs RE, Engel WK. Effects of acetazolamide on myotonia. Annals of Neurology 1978;3(6):531-7.
22. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989;39(2 Pt 1):219-22.
23. Guilleminault C, Flagg WH, Coburn SC, Dement WC. Baclofen trial in six myotonic dystrophy patients. Acta Neurologica Scandinavica 1978;57(3):232-8.
24. Hughes EF, Wilson J. Response to treatment with antihistamines in a family with myotonia congenita. Lancet 1991;337(8732):28-30.
25. Jackson CE, Barohn RJ, Ptacek LJ. Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle and Nerve 1994;17(7):763-8.
26. Karli P, Bergstrom L. Effect of baclofen on myotonia. Lancet 1974;1(7869):1285-6.
27. Matsumura T, Yokoe M, Nakamori M, Hattori N, Saito T, Nozaki S, et al. A clinical trial of creatine monohydrate in muscular dystrophy patients. Clinical Neurology 2004;44(10):661-6.
28. Mielke U, Haass A, Sen S, Schmidt W. Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. Journal of Neurology 1985;232(5):271-4.
29. Milner-Brown HS, Miller RG. Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Archives of physical medicine and rehabilitation 1990;71(12):983-7.
30. Müller D, Leuschner U. Clinical and neurophysiological findings in serum controlled diphenylhydantoin application - considerations on myotonic dystrophy therapy [Klinische und neurophysiologische befunde bei blutspiegelkontrollierter diphenylhydantoinapplikation - überlegung zur therapie der myotonen dystrophie]. Psychiatrie, Neurologie, und medizinische Psychologie 1980;32(8):464-8.
31. Orndahl G, Sellden U, Hallin S, Wetterqvist H, Rindby A, Selin E. Myotonic dystrophy treated with selenium and vitamin E. Acta Medica Scandinavica 1986;219(4):407-14.
32. Orndahl G, Grimby G, Grimby A, Johansson G, Wilhelmsen L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. Journal of internal medicine 1994;235(3):205-10.
33. Pendefunda GH, Stefanache F, Cozma V. The treatment of myotonia with L-Dopa. Clinical and electromyographic study. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 1974;78(3):591-602.
34. Pénisson-Besnier I, Devillers M, Porcher R, Orlikowski D, Doppler V, Desnuelle C, et al. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology 2008;71(6):407-12.
35. Ricker K, Haass A, Rudel R, Bohlen R, Mertens HG. Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide. Journal of Neurology, Neurosurgery, and Psychiatry 1980;43(3):268-71.
36. Rüdel R, Dengler R, Ricker K, Haass A, Emser W. Improved therapy of myotonia with the lidocaine derivative tocainide. Journal of Neurology 1980;222(4):275-8.
37. Samaha FJ. Von Eulenberg's paramyotonia. A clinical study of restricted myotonia and episodic paralysis successfully controlled by chlorothiazide. Transactions of the American Neurological Association 1964;89:87-91.
38. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo controlled clinical study. Proximal myotonic myopathy. Neurology 2003;60(3):500-2.
39. Sechi GP, Traccis S, Durelli L, Monaco F, Mutani R. Carbamazepine versus diphenylhydantoin in the treatment of myotonia. European Neurology 1983;22(2):113-8.
40. Streib EW. Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients. Muscle & Nerve 1987;10(2):155-62.
41. Sugino M, Ohsawa N, Ito T, Ishida S, Yamasaki H, Kimura F, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51(2):586-9.
42. Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle & Nerve 2004;29(1):51-8.
43. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy - a clinical research center study. The Journal of Clinical Endocrinology and Metabolism 1995;80(12):3715-23.
44. Walter MC, Reilich P, Lochmuller H, Kohnen R, Schlotter B, Hautmann H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. Journal of Neurology 2002;249(12):1717-22.
45. Martens WB, Moxley III RT, Logigian EL, McDermott M, Thornton CA, Wiegner AW, et al. Mexiletine: Effective antimyotonia treatment in myotonic dystrophy type I (DM1). Neurology 2005;64(Suppl 1):A413.
46. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publication, 1987:119.
47. Baumann P, Myllyla R, Leisti J. Myotonia congenita in northern Finland: an epidemiological and genetic study. Journal of Medical Genetics 1998;35(4):293-6.
48. Becker PE. Paramyotonia Congenita (Eulenburg). Stuttgart: George Thieme Verlag, 1970.
49. Becker PE, Knussmann R, Kuhn E. Myotonia congenita and syndromes associated with myotonia. Clinical-genetic studies of the nondystrophic myotonias. Stuttgart: George Thieme Publishers, 1977.
50. Bernareggi A, Furling D, Mouly V, Ruzzier F, Sciancalepore M. Myocytes from congenital myotonic dystrophy display abnormal Na+ channel activities. Muscle & Nerve 2005;31(4):506-9.
51. Bowman WC. Effects of adrenergic activators and inhibitors on the skeletal muscles. In: Szekeres L editor(s). Handbook of experimental pharmacology: Adrenergic Activators and inhibitors, part II. Vol. 54/II, Berlin, Springer-Verlag, 1981:47-128.
52. Breslow NE, Day NE. Statistical Methods in Cancer Research: The analysis of case-control studies. Vol. I, Lyon: International Agency for Research in Cancer, 1980:165.
53. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3'end of a transcript encoding a protein kinase family member. Cell 1992;69(2):385.
54. Ceccarelli M, Rossi B, Siciliano G, Calevro L, Tarantino E. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatrica 1992;81(5):453-5.
55. Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Molecular Cell 2002;10(1):45-53.
56. Cürschmann H. [Über famili äre atrophische myotonie]. Deutsche Zeitschrift für Nervenheilkünde 1912;45:161-202.
57. Dengler R, Rudel R. Effects of tocainide on normal and myotonic mammalian skeletal muscle. Arzneimittelforschung 1979;29(2):270-3.
58. Drost G, Blok JH, Stegeman DF, van Dijk JP, van Engelen BG, Zwarts MJ. Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: a high density surface EMG study. Brain 2001;124(2):352-60.
59. Dukes MNG, Aronson JK, editors. Meyler's side effects of drugs. 12th Edition. Oxford: Elsevier, 2000.
60. Durelli L, Mutani R, Sechi GP, Monaco F, Glorioso N, Gusmaroli G. Cardiac side effects of phenytoin and carbamazepine. A dose-related phenomenon?. Archives of Neurology 1985;42(11):1067-8.
61. Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscular Disorders 1991;1(1):19-29.
62. Fontaine B, Khurana TS, Hoffman EP, Bruns GA, Haines JL, Trofatter JA, et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science 1990;250(4983):1000-2.
63. Fontaine B, Plassart-Schiess E, Nicole S. Diseases caused by voltage-gated ion channels. Molecular Aspects of Medicine 1997;18(6):415-63.
64. Fowler WM Jr, Layzer RB, Taylor RG, Eberle ED, Sims GE, Munsat TL, et al. The Schwartz-Jampel syndrome. Its clinical, physiological and histological expressions. Journal of the Neurological Sciences 1974;22(1):127-46.
65. Franke C, Laizzo PA, Hatt H, Spittelmeister W, Ricker K, Lehmann-Horn F. Altered Na+ channel activity and reduced Cl- conductance cause hyperexcitability in recessive generalized myotonia (Becker). Muscle & Nerve 1991;14(8):762-70.
66. Gelfand MS, Yunus F, White FL. Bone marrow granulomas, fever, pancytopenia, and lupus-like syndrome due to tocainide. The southern medical journal 1994;87(8):839-41.
67. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nature Genetics 1993;3(4):305-10.
68. Harley HG, Rundle SA, Reardon W, Myring J, Crow S, Brook JD, et al. Unstable DNA sequence in myotonic dystrophy. Lancet 1992;339(8802):1125-8.
69. Harper PS. Other myotonic disorders and muscular dystrophies: the differential diagnosis of myotonic dystrophy. Myotonic dystrophy. 3rd Edition. London and Philadelphia: WB Saunders, 2001:47-89.
70. Harper PS. Myotonic dystrophy: a multisystemic disorder. In: Harper PS, van Engelen B, Eymard B, Wilcox DE editor(s). Myotonic Dystrophy. New York: Oxford University Press, 2004:3-13.
71. Howeler CJ, Busch HFM, Geraedts JP, Niermeijer MF, Staal A. Anticipation in myotonic dystrophy: fact or fiction?. Brain 1989;112(Pt 3):779-97.
72. Jurkat-Rott K, Lehmann-Horn F, Rudel R. Chloride and sodium channel myotonias. In: Rose MR, Griggs RC editor(s). Channelopathies of the nervous system. Oxford: Butterworth-Heinemann, 2001.
73. Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257(5071):797-800.
74. Koty PP, Pegoraro E, Hobson G, Marks HG, Turel A, Flagler D, et al. Myotonia and the muscle chloride channel: dominant mutations show variable penetrance and founder effect. Neurology 1996;47(4):963-8.
75. Leheup B, Himon F, Morali A, Brichet F, Vidailhet M. Value of mexiletine in the treatment of Thomsen-Becker myotonia [Interêt de la mexiletine dans le traitement de la myotonie de Thomsen-Becker]. Archives Françaises de Pédiatrie 1986;43(1):49-50.
76. Lehmann-Horn F, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R. Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH. Muscle & Nerve 1987;10(4):363-74.
77. Lehmann-Horn F, Rudel R, Ricker K. Membrane defects in paramyotonia congenita (Eulenburg). Muscle & Nerve 1987;10(7):633-41.
78. Lehmann-Horn F, Engel AG, Ricker K, Rudel R. The periodic paralyses and paramyotonia congenita. In: Engel AG, Franzini-Armstrong C editor(s). Myology. New York: McGraw-Hill, 1994:1303-34.
79. Lennox G, Purves A, Marsden D. Myotonia fluctuans. Archives of Neurology 1992;49(10):1010-1.
80. Lerche H, Heine R, Pika U, George AL Jr, Mitrovic N, Browatzki M, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. The Journal of Physiology 1993;470:13-22.
81. Lipicky RJ. Myotonic disorders other than myotonic dystrophy. In: Vinken PJ, Bruyn GW editor(s). Handbook of Clinical Neurology. Amsterdam: Elsevier, 1979:533-71.
82. Boer de JE, Danz M, 't Erve van EHM, Jong de JM, Oppenraay MLHA, Mes NTh, et al. In: Loenen van AC editor(s). Farmacotherapeutisch kompas. Utrecht: Roto Smeets Utrecht, 2005.
83. Logigian EL, Moxley RT 4th, Blood CL, Barbieri CA, Martens WB, Wiegner AW, et al. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology 2004;62(7):1081-9.
84. Logigian EL, Blood CL, Dilek N, Martens WB, Moxley RT 4th, Wiegner AW, Thornton CA, Moxley RT 3rd. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle & Nerve 2005;32(1):35-42.
85. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Molecular Cell 2002;10(1):35-44.
86. Meola G, Sansone V. Therapy in myotonic disorders and in muscle channelopathies. Journal of the Neurological Sciences 2000;21(Suppl):953-61.
87. Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Revue neurologique 2004;160(5 Pt 2):S55-69.
88. Moxley RT 3rd. Proximal myotonic myopathy: mini review of a recently delineated clinical disorder. Neuromuscular Disorders 1996;6(2):87-93.
89. Nelson JC, Lutton JD, Fass AE. Procainamide-induced agranulocytosis with reversible myeloid sensitivity. American Journal of Hematology 1984;17(4):427-32.
90. Papponen H, Toppinen T, Baumann P, Myllyla V, Leisti J, Kuivaniemi H, et al. Founder mutations and the high prevalence of myotonia congenita in northern Finland. Neurology 1999;53(2):297-302.
91. Plassart-Schiess E, Gervais A, Eymard B, Lagueny A, Pouget J, Warter JM, et al. Novel muscle chloride channel (CLCN1) mutations in myotonia congenita with various modes of inheritance including incomplete dominance and penetrance. Neurology 1998;50(4):1176-9.
92. Pouget J, Serratrice G. Myotonia with muscular weakness corrected by exercise: the therapeutic effect of mexiletine [Myotonia avec faiblesse musculaire corrigée par l' exercise. Effect therapeutique de la mexiletine]. Revue Neurologique 1983;139(4):665-72.
93. Ptácek LJ, Tawil R, Griggs RC, Meola G, McManis P, Barohn RJ, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalemic periodic paralysis. Neurology 1994;44(8):1500-3.
94. Ptácek LJ. The familial periodic paralyses and nondystrophic myotonias. The American Journal of Medicine 1998;105(1):58-70.
95. Ricker K, Haass A, Hertel G, Mertens HG. Transient muscular weakness in severe recessive myotonia congenita. Improvement of isometric muscle force by drugs relieving myotonic stiffness. Journal of Neurology 1978;218(4):253-62.
96. Ricker K, Lehmann-Horn F, Moxley RT 3rd. Myotonia fluctuans. Archives of Neurology 1990;47(3):268-72.
97. Ricker K, Moxley RT, 3rd, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Archives of Neurology 1994;51(11):1095-102.
98. Ricker K. Myotonic dystrophy and proximal myotonic myopathy. Journal of Neurology 1999;246(5):334-8.
99. Rossi B, Siciliano G, Sartucci F. Electrophysiological evaluation of congenital myotonia. Electromyography and Clinical Neurophysiology 1985;25(6):413-22.
100. Rüdel R. Altered excitability of the muscle cell membrane. The non-dystrophic myotonias. In: Engel AG, Franzini-Armstrong C editor(s). Myology. New York: Mc Graw-Hill, 1994:1291-302.
101. Rüdel R, Lehmann-Horn F. Paramyotonia, potassium-aggravated myotonias and periodic paralyses. 37th ENMC International Workshop, Naarden, The Netherlands, 8-10 December 1995. Neuromuscular Disorders 1997;7(2):127-32.
102. Rüdel R, Jurkat-Rott K, Lehmann-Horn F. Muscle ion channelopathies. Acta Myologica 1999;3:127-42.
103. Sansone V, Marinou K, Salvucci J, Meola G. Quantitative myotonia assessment: an experimental protocol. Neurological Sciences 2000;21(5 Suppl):S971-4.
104. Shields AF, Berenson JA. Procainamide-associated pancytopenia. American Journal of Hematology 1988;27(4):299-301.
105. Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Archives of Internal Medicine 1987;147(3):598-9.
106. Steinert H. [Ein neuer fall von atrophischer myotonie: ein nachtag zu meiner arbeit in Bild 37]. Deutsche Zeitschrift für Nervenheilkünde 1910;39:168-73.
107. Streib EW. Successful treatment with tocainide of recessive generalized congenital myotonia. Annals of Neurology 1986;19(5):501-4.
108. Thomsen J. Tonische krampfe in willkurlich beweglichen muskeln in folge von erebter psychischer disposition (Ataxia muscularis?). Archiv für Psychiatrie und Nervenkrankheiten 1876;6:702-18.
109. Wang RI, Schuller G. Agranulocytosis following procainamide administration. American Heart Journal 1969;78(2):282-4.
110. Wolf A. Quinine: an effective form of treatment of myotonia. Archives of Neurology and Psychiatry 1936;36:382-4.